- $7.45m
- -$8.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 0.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -360.61% | ||
| Return on Equity | -224.18% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Directors
- Andrew Koven NEC (63)
- Gil Price PRE
- Akash Bakshi COO (32)
- Andrew Bartynski SVP
- Nadja Mannowetz SVP
- jeong Gu Kang DRC (49)
- Na Yeon Kim DRC (44)
- Jason Groves IND (50)
- Hyung Kim IND
- Michael Salsbury IND (71)
- D. Gordon Strickland IND (75)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 30th, 2014
- Public Since
- August 5th, 2016
- No. of Shareholders
- 52
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 10,084,869
- Address
- 545 Concord Avenue, Suite 210, CAMBRIDGE, 02138
- Web
- https://metaviatx.com/
- Phone
- +1 8577029600
- Auditors
- BDO USA, P.C.
Upcoming Events for MTVA
Neurobo Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 NeuroBo Pharmaceuticals Inc Earnings Release
Similar to MTVA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the MetaVia share price?
As of Today at 22:01 UTC, shares in MetaVia are trading at $0.74. This share price information is delayed by 15 minutes.
How has the MetaVia share price performed this year?
Shares in MetaVia last closed at $0.74 and the price had moved by -78.64% over the past 365 days. In terms of relative price strength the MetaVia share price has underperformed the S&P500 Index by -79.92% over the past year.
What are the analyst and broker recommendations for MetaVia?
The overall consensus recommendation for MetaVia is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the MetaVia dividend yield?
MetaVia does not currently pay a dividend.
Does MetaVia pay a dividend?
MetaVia does not currently pay a dividend.
When does MetaVia next pay dividends?
MetaVia does not currently pay a dividend.
How do I buy MetaVia shares?
To buy shares in MetaVia you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of MetaVia?
As of the previous close price of $0.74, shares in MetaVia had a market capitalisation of $7.45m.
Where are MetaVia shares listed?
Here are the trading details for MetaVia:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MTVA
What kind of share is MetaVia?
Based on an overall assessment of its quality, value and momentum MetaVia is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a MetaVia share price forecast for 2025?
The analyst consensus target price for shares in MetaVia is $15.50. That is 1997.43% above the last closing price of $0.74.
Analysts covering MetaVia currently have a consensus Earnings Per Share (EPS) forecast of -$1.97 for the next financial year.
Find out moreWhat is the trend in the MetaVia share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MetaVia. Over the past six months, its share price has underperformed the S&P500 Index by -72.97%.
As of the last closing price of $0.74, shares in MetaVia were trading -71.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the MetaVia PE Ratio?
The MetaVia PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of MetaVia?
MetaVia's management team is headed by:
- Andrew Koven - NEC
- Gil Price - PRE
- Akash Bakshi - COO
- Andrew Bartynski - SVP
- Nadja Mannowetz - SVP
- jeong Gu Kang - DRC
- Na Yeon Kim - DRC
- Jason Groves - IND
- Hyung Kim - IND
- Michael Salsbury - IND
- D. Gordon Strickland - IND